The State of the Pharmaceutical Industry

PHARMACEUTICAL INDUSTRY + $1.1 TRILLION BY 2014. WORLDWIDE PHARMACEUTICAL SALES ARE EXPECTED TO INCREASE AT A COMPOUND ANNUAL RECENT TRENDS AND CHALLENGES GROWTH RATE OF 5-8%. FUELING THESE GAINS ARE PROJECTED DOUBLE-DIGIT GROWTH RATES IN EMERGING ECONOMIES. THE CHALLENGES THE OPPORTUNITIES EXPIRING PATENTS HEALTHCARE REFORM 32 MILLION V$142 billion 2011 ADDITIONAL PEOPLE WILL HAVE HEALTH INSURANCE AND ACCESS TO PRESCRIPTION DRUGS UNDER THE 2015 NEW HEALTH PLAN. AS PRODUCTS COME OFF PATENT PROTECTION, MANY LARGE FIRMS ARE AT RISK OF REVENUE REDUCTION OF UP TO 30-40%. OUTSOURCING, COLLABORATIVE PARTNERSHIPS AND STRATEGIC ALLIANCES WITHIN THE INDUSTRY ARE FORGING NEW BUSINESS MODELS. GROWTH OF GENERICS THE US GENERICS MARKET IS ANTICIPATED TO GROW 10% ANNUALLY DURING 2010-2013, FUELED BY THE PRESSURE TO REDUCE COSTS IN HEALTHCARE, THE EXPIRATION OF PATENTS AND THE ESTABLISHMENT OF AN APPROVAL PATHWAY FOR BIOSIMILARS. 2x THE 65+ SEGMENT OF THE POPULATION WILL NEARLY DOUBLE BETWEEN 2010 AND 2030. ON AVERAGE, THOSE OVER 65 YEARS OLD TAKE BETWEEN 5 TO 6 PRESCRIPTION MEDICINES. DRUG RECALLS 1309% Progressive pharmaceutical companies are realizing that in order to respond to these pressures and command a competitive position in the marketplace, they must take a new approach to their overall workforce strategy, finding new strategies for accessing and deploying critical talent where and when they need it. IN 2009 CONCERNSOVER SAFETY AND SUPPLY CHAIN QUALITY HAVE SURGED. KELLY. Sources: Business Monitor International (BMI) 042010; Census.gov; CNN.com, Fda.gov; IMS Health; Yahoo! Finance PHARMACEUTICAL INDUSTRY + $1.1 TRILLION BY 2014. WORLDWIDE PHARMACEUTICAL SALES ARE EXPECTED TO INCREASE AT A COMPOUND ANNUAL RECENT TRENDS AND CHALLENGES GROWTH RATE OF 5-8%. FUELING THESE GAINS ARE PROJECTED DOUBLE-DIGIT GROWTH RATES IN EMERGING ECONOMIES. THE CHALLENGES THE OPPORTUNITIES EXPIRING PATENTS HEALTHCARE REFORM 32 MILLION V$142 billion 2011 ADDITIONAL PEOPLE WILL HAVE HEALTH INSURANCE AND ACCESS TO PRESCRIPTION DRUGS UNDER THE 2015 NEW HEALTH PLAN. AS PRODUCTS COME OFF PATENT PROTECTION, MANY LARGE FIRMS ARE AT RISK OF REVENUE REDUCTION OF UP TO 30-40%. OUTSOURCING, COLLABORATIVE PARTNERSHIPS AND STRATEGIC ALLIANCES WITHIN THE INDUSTRY ARE FORGING NEW BUSINESS MODELS. GROWTH OF GENERICS THE US GENERICS MARKET IS ANTICIPATED TO GROW 10% ANNUALLY DURING 2010-2013, FUELED BY THE PRESSURE TO REDUCE COSTS IN HEALTHCARE, THE EXPIRATION OF PATENTS AND THE ESTABLISHMENT OF AN APPROVAL PATHWAY FOR BIOSIMILARS. 2x THE 65+ SEGMENT OF THE POPULATION WILL NEARLY DOUBLE BETWEEN 2010 AND 2030. ON AVERAGE, THOSE OVER 65 YEARS OLD TAKE BETWEEN 5 TO 6 PRESCRIPTION MEDICINES. DRUG RECALLS 1309% Progressive pharmaceutical companies are realizing that in order to respond to these pressures and command a competitive position in the marketplace, they must take a new approach to their overall workforce strategy, finding new strategies for accessing and deploying critical talent where and when they need it. IN 2009 CONCERNSOVER SAFETY AND SUPPLY CHAIN QUALITY HAVE SURGED. KELLY. Sources: Business Monitor International (BMI) 042010; Census.gov; CNN.com, Fda.gov; IMS Health; Yahoo! Finance PHARMACEUTICAL INDUSTRY + $1.1 TRILLION BY 2014. WORLDWIDE PHARMACEUTICAL SALES ARE EXPECTED TO INCREASE AT A COMPOUND ANNUAL RECENT TRENDS AND CHALLENGES GROWTH RATE OF 5-8%. FUELING THESE GAINS ARE PROJECTED DOUBLE-DIGIT GROWTH RATES IN EMERGING ECONOMIES. THE CHALLENGES THE OPPORTUNITIES EXPIRING PATENTS HEALTHCARE REFORM 32 MILLION V$142 billion 2011 ADDITIONAL PEOPLE WILL HAVE HEALTH INSURANCE AND ACCESS TO PRESCRIPTION DRUGS UNDER THE 2015 NEW HEALTH PLAN. AS PRODUCTS COME OFF PATENT PROTECTION, MANY LARGE FIRMS ARE AT RISK OF REVENUE REDUCTION OF UP TO 30-40%. OUTSOURCING, COLLABORATIVE PARTNERSHIPS AND STRATEGIC ALLIANCES WITHIN THE INDUSTRY ARE FORGING NEW BUSINESS MODELS. GROWTH OF GENERICS THE US GENERICS MARKET IS ANTICIPATED TO GROW 10% ANNUALLY DURING 2010-2013, FUELED BY THE PRESSURE TO REDUCE COSTS IN HEALTHCARE, THE EXPIRATION OF PATENTS AND THE ESTABLISHMENT OF AN APPROVAL PATHWAY FOR BIOSIMILARS. 2x THE 65+ SEGMENT OF THE POPULATION WILL NEARLY DOUBLE BETWEEN 2010 AND 2030. ON AVERAGE, THOSE OVER 65 YEARS OLD TAKE BETWEEN 5 TO 6 PRESCRIPTION MEDICINES. DRUG RECALLS 1309% Progressive pharmaceutical companies are realizing that in order to respond to these pressures and command a competitive position in the marketplace, they must take a new approach to their overall workforce strategy, finding new strategies for accessing and deploying critical talent where and when they need it. IN 2009 CONCERNSOVER SAFETY AND SUPPLY CHAIN QUALITY HAVE SURGED. KELLY. Sources: Business Monitor International (BMI) 042010; Census.gov; CNN.com, Fda.gov; IMS Health; Yahoo! Finance PHARMACEUTICAL INDUSTRY + $1.1 TRILLION BY 2014. WORLDWIDE PHARMACEUTICAL SALES ARE EXPECTED TO INCREASE AT A COMPOUND ANNUAL RECENT TRENDS AND CHALLENGES GROWTH RATE OF 5-8%. FUELING THESE GAINS ARE PROJECTED DOUBLE-DIGIT GROWTH RATES IN EMERGING ECONOMIES. THE CHALLENGES THE OPPORTUNITIES EXPIRING PATENTS HEALTHCARE REFORM 32 MILLION V$142 billion 2011 ADDITIONAL PEOPLE WILL HAVE HEALTH INSURANCE AND ACCESS TO PRESCRIPTION DRUGS UNDER THE 2015 NEW HEALTH PLAN. AS PRODUCTS COME OFF PATENT PROTECTION, MANY LARGE FIRMS ARE AT RISK OF REVENUE REDUCTION OF UP TO 30-40%. OUTSOURCING, COLLABORATIVE PARTNERSHIPS AND STRATEGIC ALLIANCES WITHIN THE INDUSTRY ARE FORGING NEW BUSINESS MODELS. GROWTH OF GENERICS THE US GENERICS MARKET IS ANTICIPATED TO GROW 10% ANNUALLY DURING 2010-2013, FUELED BY THE PRESSURE TO REDUCE COSTS IN HEALTHCARE, THE EXPIRATION OF PATENTS AND THE ESTABLISHMENT OF AN APPROVAL PATHWAY FOR BIOSIMILARS. 2x THE 65+ SEGMENT OF THE POPULATION WILL NEARLY DOUBLE BETWEEN 2010 AND 2030. ON AVERAGE, THOSE OVER 65 YEARS OLD TAKE BETWEEN 5 TO 6 PRESCRIPTION MEDICINES. DRUG RECALLS 1309% Progressive pharmaceutical companies are realizing that in order to respond to these pressures and command a competitive position in the marketplace, they must take a new approach to their overall workforce strategy, finding new strategies for accessing and deploying critical talent where and when they need it. IN 2009 CONCERNSOVER SAFETY AND SUPPLY CHAIN QUALITY HAVE SURGED. KELLY. Sources: Business Monitor International (BMI) 042010; Census.gov; CNN.com, Fda.gov; IMS Health; Yahoo! Finance PHARMACEUTICAL INDUSTRY + $1.1 TRILLION BY 2014. WORLDWIDE PHARMACEUTICAL SALES ARE EXPECTED TO INCREASE AT A COMPOUND ANNUAL RECENT TRENDS AND CHALLENGES GROWTH RATE OF 5-8%. FUELING THESE GAINS ARE PROJECTED DOUBLE-DIGIT GROWTH RATES IN EMERGING ECONOMIES. THE CHALLENGES THE OPPORTUNITIES EXPIRING PATENTS HEALTHCARE REFORM 32 MILLION V$142 billion 2011 ADDITIONAL PEOPLE WILL HAVE HEALTH INSURANCE AND ACCESS TO PRESCRIPTION DRUGS UNDER THE 2015 NEW HEALTH PLAN. AS PRODUCTS COME OFF PATENT PROTECTION, MANY LARGE FIRMS ARE AT RISK OF REVENUE REDUCTION OF UP TO 30-40%. OUTSOURCING, COLLABORATIVE PARTNERSHIPS AND STRATEGIC ALLIANCES WITHIN THE INDUSTRY ARE FORGING NEW BUSINESS MODELS. GROWTH OF GENERICS THE US GENERICS MARKET IS ANTICIPATED TO GROW 10% ANNUALLY DURING 2010-2013, FUELED BY THE PRESSURE TO REDUCE COSTS IN HEALTHCARE, THE EXPIRATION OF PATENTS AND THE ESTABLISHMENT OF AN APPROVAL PATHWAY FOR BIOSIMILARS. 2x THE 65+ SEGMENT OF THE POPULATION WILL NEARLY DOUBLE BETWEEN 2010 AND 2030. ON AVERAGE, THOSE OVER 65 YEARS OLD TAKE BETWEEN 5 TO 6 PRESCRIPTION MEDICINES. DRUG RECALLS 1309% Progressive pharmaceutical companies are realizing that in order to respond to these pressures and command a competitive position in the marketplace, they must take a new approach to their overall workforce strategy, finding new strategies for accessing and deploying critical talent where and when they need it. IN 2009 CONCERNSOVER SAFETY AND SUPPLY CHAIN QUALITY HAVE SURGED. KELLY. Sources: Business Monitor International (BMI) 042010; Census.gov; CNN.com, Fda.gov; IMS Health; Yahoo! Finance PHARMACEUTICAL INDUSTRY + $1.1 TRILLION BY 2014. WORLDWIDE PHARMACEUTICAL SALES ARE EXPECTED TO INCREASE AT A COMPOUND ANNUAL RECENT TRENDS AND CHALLENGES GROWTH RATE OF 5-8%. FUELING THESE GAINS ARE PROJECTED DOUBLE-DIGIT GROWTH RATES IN EMERGING ECONOMIES. THE CHALLENGES THE OPPORTUNITIES EXPIRING PATENTS HEALTHCARE REFORM 32 MILLION V$142 billion 2011 ADDITIONAL PEOPLE WILL HAVE HEALTH INSURANCE AND ACCESS TO PRESCRIPTION DRUGS UNDER THE 2015 NEW HEALTH PLAN. AS PRODUCTS COME OFF PATENT PROTECTION, MANY LARGE FIRMS ARE AT RISK OF REVENUE REDUCTION OF UP TO 30-40%. OUTSOURCING, COLLABORATIVE PARTNERSHIPS AND STRATEGIC ALLIANCES WITHIN THE INDUSTRY ARE FORGING NEW BUSINESS MODELS. GROWTH OF GENERICS THE US GENERICS MARKET IS ANTICIPATED TO GROW 10% ANNUALLY DURING 2010-2013, FUELED BY THE PRESSURE TO REDUCE COSTS IN HEALTHCARE, THE EXPIRATION OF PATENTS AND THE ESTABLISHMENT OF AN APPROVAL PATHWAY FOR BIOSIMILARS. 2x THE 65+ SEGMENT OF THE POPULATION WILL NEARLY DOUBLE BETWEEN 2010 AND 2030. ON AVERAGE, THOSE OVER 65 YEARS OLD TAKE BETWEEN 5 TO 6 PRESCRIPTION MEDICINES. DRUG RECALLS 1309% Progressive pharmaceutical companies are realizing that in order to respond to these pressures and command a competitive position in the marketplace, they must take a new approach to their overall workforce strategy, finding new strategies for accessing and deploying critical talent where and when they need it. IN 2009 CONCERNSOVER SAFETY AND SUPPLY CHAIN QUALITY HAVE SURGED. KELLY. Sources: Business Monitor International (BMI) 042010; Census.gov; CNN.com, Fda.gov; IMS Health; Yahoo! Finance